Theme

Session Title

Ependymoma(basic)

Tumor-type
specific Sessions

Ependymoma(clinical)

Presentation
No.

Abstract
No.

Lecture title

EPEB-IS-01

SPKR-30

Ependymoma, an increasingly less enigmatic disease

EPEB-O-02

EPEN-04

Oncogenic 3D tumor genome organization identifies new therapeutic targets in ependymoma Lukas Chavez

EPEB-O-03

EPEN-31

EPEB-O-04

EPEN-18

EPEB-O-05

EPEN-41

EPEB-O-06

EPEN-52

EPEB-P-07

EPEN-30

EPEB-P-08

EPEN-43

EPEB-P-09

EPEN-20

EPEB-P-10

EPEN-21

EPEB-P-11

EPEN-16

EPEB-P-12

Speaker
Kristian Pajtler

Single-cell RNAseq of childhood ependymoma reveals distinct neoplastic cell subpopulations
Andrew Donson
that impact etiology, molecular classification and outcome
Cross-species genomics identifies GLI2 as an oncogene of C11orf95 fusion-positive
Tuyu Zheng
supratentorial ependymoma
C11orf95-RELA fusion regulates aberrant gene expression through the unique genomic
Tatsuya Ozawa
binding sites for ependymoma formation

Country
Germany
USAUSA
GermanyJapan

Sachin Kumar

CanadaStephen MackUSA

Alina Pandele

UKEmily KaganUSABernhard Englinger

USA

Transcriptional regulatory circuitries as molecular targets in ependymoma

Kelsey Bertrand

USA

EPEN-22

Single-cell RNA sequencing identifies upregulation of IKZF1 in PFA2 myeloid subpopulation
driving an anti-tumor phenotype

Andrea Griesinger

USAEPEB-P-13

EPEN-42

Molecular profiling reveals distinct subgroups of pediatric spinal ependymoma

Anbarasu Lourdusamy

UK

EPEB-P-14

EPEN-27

Torsten Pietsch

Germany

EPEB-P-15

EPEN-33David Pauck

Germany

EPEB-P-16

EPEN-23

EPEB-P-17

EPEN-26

EPEB-P-18

EPEN-34

EPEB-P-19

EPEN-14

EPEB-P-20

EPEN-44

EPEB-P-21

EPEN-46

EPEB-P-22

Metabolic regulation of the epigenome drives lethal infantile ependymoma
C11ORF95-RELA fusion protein engages novel genomic loci to drive murine ependymoma
growthTargeting intra-tumour heterogeneity in paediatric ependymoma: an integrated omics study
towards patient-tailored therapy
EZHIP/CATACOMB cooperates with PDGF-A and p53 loss to generate a geneticallyengineered mouse model for posterior fossa A ependymoma
Impaired neuronal-glial fate specification in pediatric ependymoma revealed by single-cellRNA-Seq

CDKN2Adeletion in supratentorial ependymoma with RELAalteration indicates a dismal
prognosis – a retrospective analysis of the HIT ependymoma trial cohort
Pharmacogenomics reveals synergistic inhibition of ERBB2 and PI3K signaling as atherapeutic strategy for ependymoma.

A computational analysis of the tumour immune microenvironment in paediatric ependymoma Timothy Ritzmann
Non-canonical NF-κB signaling drives mesenchymal ependymal cell subpopulation in PFA
ependymoma
The CRISPR-Cas9 system-mediated endogenous gene rearrangement induced C11orf95RELA fusion in vitro and in vivo that led to the development of ependymoma-like tumor
Generation of a C11orf95-RELA fusion targeting antibody as a diagnostic tool forsupratentorial ependymoma
Extracellular vesicles of supratentorial ependymoma RELA mediate interactions with cells of
the tumor microenvironment

UK

Andrea Griesinger

USA

Mutsumi Takadera

Japan

Lisa Ruff

UK

Kendra Maass

Germany

DNA methylation landscape of recurrent pediatric ependymoma identifies key driver events

Sibo Zhao

USAEPEN-05

Clinical and genetic evolution of ependymoma exposed from a multi-recurrence girl caseZhong-ping Chen

China

EPEB-P-23

EPEN-47

PEDS: Pediatric ependymoma discovery study

Amy Smith

USAEPEC-IS-01

SPKR-19

EPEC-O-02

EPEN-54

EPEC-O-03

EPEN-09

EPEC-O-04

EPEN-03

Long-term follow-up of AIEOP 2nd series of children and adolescent with primary intracranial(ST:supratentorial; PF: posterior fossa) ependymoma and methylation groups re-analyses

Maura Massimino

Italy

EPEC-O-05

EPEN-06

Chemotherapy of recurrent ependymoma: long-term response only in few cases

Jonas Adolph

Germany

EPEC-O-06

EPEN-39

Denise Obrecht

Germany

EPEC-P-07

EPEN-02

Keishi Makino

JapanEPEC-P-08

EPEN-10

Sumit Gupta

USAEPEC-P-09

EPEN-37

Treatment outcome of recurrent ependymoma in children in Northern Egypt

Shady Fadel

Egypt

EPEC-P-10

EPEN-36

The treatment outcome of paediatric supratentorial C11orf95-RELA fused ependymoma: A
combined report from E-HIT series and Australian New Zealand Children’s
Haematology/Oncology Group

Chia Huan Ng

Australia

EPEC-P-11

EPEN-45

Normalizing and facilitating genomic testing at diagnosis in pediatric ependymoma

Emily Owens Pickle

USA

EPEC-P-12

EPEN-07

EPEC-P-13

EPEN-24

EPEC-P-14

EPEN-38

EPEC-P-15

EPEN-01

EPEC-P-16

EPEN-49

EPEC-P-17

EPEN-50

EPEC-P-18

EPEN-25

EPEC-P-19

EPEN-28

EPEC-P-20

Posterior Fossa Ependymoma (PF EPN): Reaching for Effective Therapy while exploring new
Nicholas Foreman
Biology.
ACNS0831, Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients withAmy Smith
Newly Diagnosed Ependymoma Ages 1 to 21 years
Impact of molecular subgroup on outcome for infants <12 months with intracranialDenise Obrecht
ependymoma - German experience from HIT2000, Interim-2000-registry and I-HIT-MED
registry

Clinical stratified treatment of localized pediatric intracranial ependymoma with combined
local irradiation and chemotherapy within the prospective, multicenter E-HIT trial – themolecular subgroup matters
Evaluation of treatment outcomes and expression of EMT-related transcription factors as
novel therapeutic targets in pediatric ependymoma
Spinal myxopapillary ependymoma and methylation-profiling: The MD Anderson Cancer
Center (MDACC) experience

Patterns of extraneural metastases in pediatric supratentorial ependymoma: case series andPriya Chanreview of the literature
SIOP Ependymoma II: Central Ependymoma Management Advisory Group – The UKRichard Grundy
Experience
EZH2 inhibitory protein (EZHIP/Cxorf67) expression is highly concordant with H3K27me3 loss
Aruna Nambirajan
and is a promising surrogate marker for posterior fossa type A ependymomas

USAUSA
GermanyUSA
UKIndia

Daisuke Hirokawa

Japan

Eileen Gillan

USAJohn Lucas

USA

Ross Mangum

USA

Novel oncogene amplification in spinal ependymoma involving the myc locus (8q24)

Margaret Shatara

USAEPEN-17

Favorable outcome to intensive chemotherapy without irradiation in infantile metastaticependymoma with a novel molecular profile: a case report

Flavia de Faria

BrazilEPEC-P-21

EPEN-35

Peritoneal carcinomatosis of anaplastic ependymoma: First reported caseJonathan Schwartz

USAEPEC-P-22

EPEN-51

Childhood intracranial ependymoma: a multi-center retrospective analysis

Amy SmithUSA

EPEC-P-23

EPEN-11

EPEC-P-24

EPEN-13

EPEC-O-25

EPEN-53

Multidisciplinary treatment in ependymoma
Response of recurrent ependymoma to MEMMAT based metronomic antiangiogenic
combination therapy utilizing tapered bevacizumab and maintenance therapy with celecoxib
and fenofibrate
The management and treatment of pediatric spinal cord ependymoma: Results from acollaborative international multi-institutional review
Exceptional clinical and imaging response to TRK-inhibition in a patient with supratentorial
ependymoma harboring NTRK2 gene fusion

Ongoing response in a multiply relapsed metastatic posterior fossa ependymoma A after
Hamza Gorsi
vorinostat and concomitant irradiation
Primary extradural sacrococcygeal subcutaneous myxopapilar ependymoma misdiagnosed asRegina Navarro-Martin del Campopilonidal cyst in a 7 year-old boy: A case report
C11orf95-RELA reprograms 3D epigenome in supratentorial ependymoma

Ching LauUSAMexicoUSA